Genus plc's (LON:GNS) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?




  • In Business
  • 2022-12-06 05:55:21Z
  • By Simply Wall St.
 

Genus (LON:GNS) has had a great run on the share market with its stock up by a significant 27% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. Particularly, we will be paying attention to Genus' ROE today.

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

See our latest analysis for Genus

How To Calculate Return On Equity?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Genus is:

6.4% = UK£37m ÷ UK£572m (Based on the trailing twelve months to June 2022).

The 'return' is the profit over the last twelve months. So, this means that for every £1 of its shareholder's investments, the company generates a profit of £0.06.

What Has ROE Got To Do With Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

A Side By Side comparison of Genus' Earnings Growth And 6.4% ROE

On the face of it, Genus' ROE is not much to talk about. Next, when compared to the average industry ROE of 18%, the company's ROE leaves us feeling even less enthusiastic. Thus, the low net income growth of 2.9% seen by Genus over the past five years could probably be the result of the low ROE.

As a next step, we compared Genus' net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 6.8% in the same period.

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Genus is trading on a high P/E or a low P/E, relative to its industry.

Is Genus Making Efficient Use Of Its Profits?

Despite having a moderate three-year median payout ratio of 50% (implying that the company retains the remaining 50% of its income), Genus' earnings growth was quite low. So there might be other factors at play here which could potentially be hampering growth. For example, the business has faced some headwinds.

Additionally, Genus has paid dividends over a period of at least ten years, which means that the company's management is determined to pay dividends even if it means little to no earnings growth. Upon studying the latest analysts' consensus data, we found that the company's future payout ratio is expected to drop to 34% over the next three years. As a result, the expected drop in Genus' payout ratio explains the anticipated rise in the company's future ROE to 11%, over the same period.

Conclusion

In total, we're a bit ambivalent about Genus' performance. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

AltynGold plc (LON:ALTN) Held Back By Insufficient Growth Even After Shares Climb 85%
AltynGold plc (LON:ALTN) Held Back By Insufficient Growth Even After Shares Climb 85%

Despite an already strong run, AltynGold plc ( LON:ALTN ) shares have been powering on, with a gain of 85% in the last...

Could The Market Be Wrong About CPT Global Limited (ASX:CGO) Given Its Attractive Financial Prospects?
Could The Market Be Wrong About CPT Global Limited (ASX:CGO) Given Its Attractive Financial Prospects?

It is hard to get excited after looking at CPT Global's (ASX:CGO) recent performance, when its stock has declined 9.9...

Does The Market Have A Low Tolerance For Compumedics Limited
Does The Market Have A Low Tolerance For Compumedics Limited's (ASX:CMP) Mixed Fundamentals?

Compumedics (ASX:CMP) has had a rough three months with its share price down 20%. We, however decided to study the...

Do Its Financials Have Any Role To Play In Driving Greenyield Berhad
Do Its Financials Have Any Role To Play In Driving Greenyield Berhad's (KLSE:GREENYB) Stock Up Recently?

Greenyield Berhad's (KLSE:GREENYB) stock is up by a considerable 5.0% over the past week. We wonder if and what role...

Investors Aren
Investors Aren't Buying Sylvamo Corporation's (NYSE:SLVM) Earnings

With a price-to-earnings (or "P/E") ratio of 5.4x Sylvamo Corporation ( NYSE:SLVM ) may be sending very bullish signals...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business